Gilead’s end-stage confirmatory trials of bladder cancer drug fail
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a
HQ Team October 19, 2024: The U.S. Food and Drug Administration (FDA) has approved AbbVei’s drug Vyalev for the treatment of advanced Parkinson’s
HQ Team October 19, 2024: Stealth startup Treeline Biosciences has raised another $421 million, one of the biggest raises of the year in
HQ Team October 18, 2024: As global greenhouse gas emissions continue to rise there is an urgency to find effective climate intervention solutions.
Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the
HQ Team October 17, 2024: Extreme weather conditions and the increasing number of natural disaster events have forced China to take steps to
HQ Team October 17, 2024: Blood pressure measurement is a critical procedure in diagnosing and managing hypertension, yet it is fraught with scientific
Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the